ArticleCancer biomarkers : section A of Disease markers
Development and verification of cell cycle-related gene markers for prognosis in bladder cancer.
Article in Cancer biomarkers : section A of Disease markers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundThe abnormal expression patterns of genes associated with cell cycle control are essential contributors to the initiation and progression of bladder cancer (BC).MethodsIn this research, transcriptomic profiles sourced from The Cancer Genome Atlas (TCGA) were examined to pinpoint cell cycle-related genes with significant expression differences between early-stage (I-II) and advanced-stage (III-IV) BC. The identified BC samples were then randomly split into training and validation groups. A prognostic model containing nine key genes was subsequently constructed from the training dataset using the least absolute shrinkage and selection operator (LASSO) regression algorithm, and its predictive reliability was independently confirmed in the validation dataset. Based on individual risk scores derived from this gene signature, patients were separated into high- and low-risk groups. Functional enrichment analyses (GO and KEGG), immune cell infiltration (CIBERSORT), and gene set variation analysis (GSVA) were performed to explore the biological functions and immune landscape associated with the risk signature.ResultsSurvival analysis revealed substantially worse overall survival (OS) in patients categorized as high-risk. The prognostic efficacy of the constructed gene signature was further corroborated by receiver operating characteristic (ROC) curve analyses. Functional enrichment analyses revealed that these genes were chiefly associated with critical biological processes such as cellular differentiation, proliferation, and migration, involving key signaling pathways like PI3K-Akt signaling, positive modulation of the MAPK cascade, and cell-matrix interactions. Immune infiltration analysis showed that tumors from patients in the high-risk group had increased infiltration by M2 macrophages. Furthermore, GSVA results indicated that stromal and angiogenic functions were enriched in the high-risk group.ConclusionsThese results highlight the potential clinical utility of the newly developed cell cycle-associated gene signature, providing effective biomarkers to facilitate personalized therapeutic decision-making for BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.